Regeneron initiates trial for pozelimab + cemdisiran in PNH patients unresponsive to C5 inhibitors
Regeneron is conducting a study to evaluate the efficacy of pozelimab and cemdisiran in PNH patients inadequately controlled by existing therapies.
Therapeutic Area
Therapeutic area intelligence for Paroxysmal Nocturnal Hemoglobinuria (PNH) with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.